mhurhangee/ep-ind-claims huggingface dataset:
A system for detecting an out-of-operation state of an elevator system, wherein the system comprises: a monitoring unit for monitoring one or more operations of the elevator system, characterised in that the system further comprises a sensor unit arranged in a vicinity of a landing call device and configured to: detect at least one event indicating a generation of an elevator call, and provide a message indicating the generation of an elevator call to the monitoring unit, and in that the monitoring unit is configured to: initiate a time measuring function in response to receiving the message from the sensor unit, and monitor a response of the elevator system to the generated elevator call. a monitoring unit for monitoring one or more operations of the elevator system, characterised in that the system further comprises a sensor unit arranged in a vicinity of a landing call device and configured to: detect at least one event indicating a generation of an elevator call, and provide a message indicating the generation of an elevator call to the monitoring unit, and in that the monitoring unit is configured to: initiate a time measuring function in response to receiving the message from the sensor unit, and monitor a response of the elevator system to the generated elevator call. detect at least one event indicating a generation of an elevator call, and provide a message indicating the generation of an elevator call to the monitoring unit, and in that the monitoring unit is configured to: initiate a time measuring function in response to receiving the message from the sensor unit, and monitor a response of the elevator system to the generated elevator call. initiate a time measuring function in response to receiving the message from the sensor unit, and monitor a response of the elevator system to the generated elevator call.
An implantable medical device (12, 112) comprising: a wall (18, 118) defining a lumen with proximal and distal ends thereof and configured to the size and shape of a portion of a cavity or hollow organ lined with the mucosa; said wall configured to press against the surface of the hollow organ or cavity in the portion of the hollow organ or cavity; a fixation mechanism (60, 160) that is adapted to fix said wall (18, 118) with the portion of the cavity or hollow organ, said fixation mechanism (60, 160) comprising at least two adjacent openings (62, 162) in said wall between said proximal and distal ends, characterized in that said at least two adjacent openings (62, 162) are separated by a bridge, each of said openings having a size that is large enough to cause the mucosa to bulge into that opening (62, 162) in a manner that maintains perfusion of the mucosa as a result of the portion of said wall including the at least two adjacent openings pressing against the portion of the hollow organ or cavity; and said adjacent openings (62, 162) configured to be close enough together that the sections of mucosa that bulge into said openings come together over said bridge to fix said medical device (12, 112) in said hollow organ or cavity. a wall (18, 118) defining a lumen with proximal and distal ends thereof and configured to the size and shape of a portion of a cavity or hollow organ lined with the mucosa; said wall configured to press against the surface of the hollow organ or cavity in the portion of the hollow organ or cavity; a fixation mechanism (60, 160) that is adapted to fix said wall (18, 118) with the portion of the cavity or hollow organ, said fixation mechanism (60, 160) comprising at least two adjacent openings (62, 162) in said wall between said proximal and distal ends, characterized in that said at least two adjacent openings (62, 162) are separated by a bridge, each of said openings having a size that is large enough to cause the mucosa to bulge into that opening (62, 162) in a manner that maintains perfusion of the mucosa as a result of the portion of said wall including the at least two adjacent openings pressing against the portion of the hollow organ or cavity; and said adjacent openings (62, 162) configured to be close enough together that the sections of mucosa that bulge into said openings come together over said bridge to fix said medical device (12, 112) in said hollow organ or cavity.
A cyclosporin or derivative thereof, or a combination thereof, for use in advance of treatment with a therapeutically active agent, said therapeutically active agent being a chemotherapy agent, an antiviral agent or an immunomodulator, in a method of prophylactically treating keratoconjunctivitis associated with the use of said therapeutically active agent.
A liquid pharmaceutical formulation for injection comprising: (i) an antibody; (ii) cimetidine or a pharmaceutically acceptable salt thereof; and (iii) a pharmaceutically acceptable solvent; wherein the liquid pharmaceutical formulation, when in a volume suitable for injection, has an absolute viscosity from about 1 mPa.s (cP) to about 100 mPa.s (cP) at 25°C as measured using a cone and plate viscometer or a microfluidic viscometer; and the absolute viscosity of the liquid pharmaceutical formulation is less than the absolute viscosity of a control formulation comprising the antibody and the pharmaceutically acceptable solvent, but without the cimetidine or a pharmaceutically acceptable salt thereof; wherein the absolute viscosity is an extrapolated zero-shear viscosity. (i) an antibody; (ii) cimetidine or a pharmaceutically acceptable salt thereof; and (iii) a pharmaceutically acceptable solvent; wherein the liquid pharmaceutical formulation, when in a volume suitable for injection, has an absolute viscosity from about 1 mPa.s (cP) to about 100 mPa.s (cP) at 25°C as measured using a cone and plate viscometer or a microfluidic viscometer; and the absolute viscosity of the liquid pharmaceutical formulation is less than the absolute viscosity of a control formulation comprising the antibody and the pharmaceutically acceptable solvent, but without the cimetidine or a pharmaceutically acceptable salt thereof; wherein the absolute viscosity is an extrapolated zero-shear viscosity.
Oral and dental care and tooth cleaning means in the form of a paste with an addition of fine-grained, water-insoluble cleaning bodies, characterized in that the cleaning bodies consist of pure native cellulose which corresponds to an untreated, natural cellulose which is obtained from vegetable precursor material by means of a pulping process and which, in contrast to microcrystalline cellulose, is not subjected to any further subsequent chemical-modifying process, and which are in the form of short-fibered particles with an irregular surface and a surface-rough structure which has a large number of elevations and depressions, and in that the cleaning bodies have an average particle size of 30 μm to 80 μm.
Method for producing tubular semi-finished products from a shape memory alloy for the production of stents comprising the steps a) a powder is produced from a shape memory alloy by gas atomisation, b) in a first separating cut T1 in the range between 1 and 100 μm, the powder is separated into a coarse fraction with an average grain size > T1 and a fine fraction with an average grain size < T1, c) the coarse fraction is subjected to a further separating cut T2 > T1 in the range from 50 to 150 μm, d) the fine fraction is used for the manufacture of a first semi-finished product using the metal injection moulding method, e) only the powder of the coarse fraction with an average grain size of between T1 and T2 is used for the manufacture of the second, tubular, semi-finished product using hot isostatic pressing. a) a powder is produced from a shape memory alloy by gas atomisation, b) in a first separating cut T1 in the range between 1 and 100 μm, the powder is separated into a coarse fraction with an average grain size > T1 and a fine fraction with an average grain size < T1, c) the coarse fraction is subjected to a further separating cut T2 > T1 in the range from 50 to 150 μm, d) the fine fraction is used for the manufacture of a first semi-finished product using the metal injection moulding method, e) only the powder of the coarse fraction with an average grain size of between T1 and T2 is used for the manufacture of the second, tubular, semi-finished product using hot isostatic pressing.
An optical phased array having a design wavelength between about 100 nm and about 1 mm and a design bandwidth, the optical phased array comprising: a wafer; a first plurality of optical couplers (104, 106, 108, 110) disposed in a predefined array, relative to the wafer; a first optical port disposed in a predefined location, relative to the wafer; and a first plurality of optical waveguides (112, 114, 116) disposed relative to the wafer and optically connecting the first plurality of optical couplers (104, 106, 108, 110) to the first port via respective first optical paths, one first optical path per first optical coupler, such that optical lengths of all the first optical paths are equal, within one coherence length at a bandwidth greater than about 0.1% plus a spacing between two maximally spaced-apart optical couplers (104, 106, 108, 110) of the first plurality of optical couplers (104, 106, 108, 110). a wafer; a first plurality of optical couplers (104, 106, 108, 110) disposed in a predefined array, relative to the wafer; a first optical port disposed in a predefined location, relative to the wafer; and a first plurality of optical waveguides (112, 114, 116) disposed relative to the wafer and optically connecting the first plurality of optical couplers (104, 106, 108, 110) to the first port via respective first optical paths, one first optical path per first optical coupler, such that optical lengths of all the first optical paths are equal, within one coherence length at a bandwidth greater than about 0.1% plus a spacing between two maximally spaced-apart optical couplers (104, 106, 108, 110) of the first plurality of optical couplers (104, 106, 108, 110).
A neurostimulator system, comprising: a pulse generator module including an electrical stimulation lead, a pulse-generator circuit and electrodes, and configured to be implanted within a body of a subject, to provide a therapy to the subject, and to receive power wirelessly from a source remote from the pulse generator module; and a power source and control module configured to be located external to the body of the subject, to cause the pulse generator module to effect the therapy, and to provide power wirelessly to the pulse generator module, characterized in that the pulse-generator circuit is disposed within the electrical stimulation lead. a pulse generator module including an electrical stimulation lead, a pulse-generator circuit and electrodes, and configured to be implanted within a body of a subject, to provide a therapy to the subject, and to receive power wirelessly from a source remote from the pulse generator module; and a power source and control module configured to be located external to the body of the subject, to cause the pulse generator module to effect the therapy, and to provide power wirelessly to the pulse generator module,
A compressor comprising: an inlet port and a discharge port, said discharge port communicating into a resonator chamber, said resonator chamber including a first stage resonator array and a second stage resonator array downstream of said first stage resonator array with a connecting passage intermediate said first and second resonator array (46, 48) and an exit port leaving the resonator chamber, a flow passage communicates the discharge port to the exit port, and passes through the first and second resonator arrays (46, 48); and each of said first and second resonator arrays (46, 48) including a pair of spaced resonator arrays sub-portions, with each of said sub-portions including a plurality of cells extending into a housing member, and having a bottom wall and an open outer wall communicating with the flow passage, with a plurality of orifices extending into each of said cells, with said orifices having a smaller diameter than a hydraulic diameter of said cells.
A pharmaceutical composition comprising an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 4 or of any functional fragments of the isolated peptide, wherein said functional fragments have at least 70% identity to SEQ ID NO: 4, for use in a method of preventing or treating cancer metastasis, wherein said cancer is a metastatic cancer.
A packing machine for producing a packet of smoking articles, which comprises an inner package enclosing at least one group of smoking articles and at least one spacer; the packing machine comprising: a group-forming unit comprising a group-forming pocket for housing the group of smoking articles and the spacer, a group-forming conveyor which feeds the group-forming pocket along a group-forming path, a first feed station located along the group-forming path to insert the spacer inside the group-forming pocket in a feed direction, and a second feed station located along the group-forming path to insert the group of smoking articles inside the group-forming pocket along the feed direction; and a packing unit which receives the group of smoking articles together with the spacer from the group-forming unit, and wraps a sheet of packing material about the group of smoking articles and the spacer to form the inner package; the packing machine being characterized in that: the group-forming pocket houses the spacer in direct contact with the group of smoking articles; and the group-forming pocket comprises at least one guide, which projects towards the inside from a wall of the group-forming pocket so as to be arranged in the space suited to receive the smoking articles, is oriented parallel to the feed direction, and engages the spacer to prevent transverse movement of the spacer inside the group-forming pocket. a group-forming unit comprising a group-forming pocket for housing the group of smoking articles and the spacer, a group-forming conveyor which feeds the group-forming pocket along a group-forming path, a first feed station located along the group-forming path to insert the spacer inside the group-forming pocket in a feed direction, and a second feed station located along the group-forming path to insert the group of smoking articles inside the group-forming pocket along the feed direction; and a packing unit which receives the group of smoking articles together with the spacer from the group-forming unit, and wraps a sheet of packing material about the group of smoking articles and the spacer to form the inner package; the group-forming pocket houses the spacer in direct contact with the group of smoking articles; and the group-forming pocket comprises at least one guide, which projects towards the inside from a wall of the group-forming pocket so as to be arranged in the space suited to receive the smoking articles, is oriented parallel to the feed direction, and engages the spacer to prevent transverse movement of the spacer inside the group-forming pocket.
A peptide of formula: R 2 -Lys 1 -Phe 2 -Asn 3 -Leu 4 -Pro 5 -Leu 6 -Gly-Asn 8 -Tyr 9 -Lys 10 -Lys 11 -Pro 12 -R 1 (R 2 -SEQ ID NO: 1-R 1) or analogues thereof in which one of the aminoacid rests 2 to 12 is replaced with an alanine rest wherein R 1 is selected from the group consisting of -OH, -OR 3, -SR 3, -NR 3 R 4, -OR 5 and -NHR 5; R 2 is selected from the group consisting of H-, R 3 -C - and R 3 -OC -, R 3 and R 4 are independently selected from H, C 1 -C 24 alkyl, C 2 -C 24 alkenyl and C 6 -C 10 aryl; R 5 is selected from the group consisting of -(CH 2) 3 -PEG-CH 2 -NH 2, -PEG-R 6, - (CH 2) n -O-PEG-R 6, -CO-O-PEG-R 6, -CO- (CH 2 CH 2)-CO-O-PEG-R 6, -CO-(CH 2) m -O-PEG-R 6, -CO-(CH 2) n -CH(R 7) -O-PEG-R 6, -CO-(CH 2) m -CH(R 7)-O-CO-CH(R 7)-(CH 2) m -O-PEG-R 6 and -(1,3,5-triazine)-(O-PEG-R 6) 2, PEG is a polyether group selected from the group consisting of - (CH 2 -CH 2 -O) n -, - (CH 2 -CH(CH 3)-O) o -, - (CH(CH 3)-CH 2 -O) o -, - (CH 2 -CH 2 -O) n -(CH 2 -CH(CH 3)-O) o -(CH 2 -CH 2 -O) p -, - (CH 2 -CH 2 -O) n -(CH(CH 3)-CH 2 -O) o -(CH 2 -CH 2 -O) p -, - (CH 2 -CH 2 -O) n -(CH(CH 3)-CH 2 -O) o -, - (CH 2 -CH 2 -O) n -(CH 2 -CH(CH 3)-O) o -, - (CH 2 -CH(CH 3)-O) o -(CH 2 -CH 2 -O) n -, - (CH(CH 3)-CH 2 -O) o -(CH 2 -CH 2 -O) n -, - (CH 2 -CH(CH 3)-O) o -(CH 2 -CH 2 -O) n -(CH 2 -CH(CH 3)-O) q -, - (CH 2 -CH(CH 3)-O) o -(CH 2 -CH 2 -O) n -(CH(CH 3)-CH 2 -O) q -, - (CH(CH 3)-CH 2 O) o -(CH 2 -CH 2 -O) n -(CH 2 -CH(CH 3)-O) q - and - (CH(CH 3)-CH 2 O) o -(CH 2 -CH 2 -O) n -(CH(CH 3)-CH 2 -O) o -, R 6 is a hydrogen atom or a C 1-4 alkyl group; and R 7 is a C 1-4 alkyl group m is an integer from 1 to 4 n and p are integers between 1 and 10 m and o are integers between 1 and 10 and cosmetically acceptable salts and solvates thereof. R 2 -Lys 1 -Phe 2 -Asn 3 -Leu 4 -Pro 5 -Leu 6 -Gly-Asn 8 -Tyr 9 -Lys 10 -Lys 11 -Pro 12 -R 1 (R 2 -SEQ ID NO: 1-R 1) - (CH 2 -CH 2 -O) n -, - (CH 2 -CH(CH 3)-O) o -, - (CH(CH 3)-CH 2 -O) o -, - (CH 2 -CH 2 -O) n -(CH 2 -CH(CH 3)-O) o -(CH 2 -CH 2 -O) p -, - (CH 2 -CH 2 -O) n -(CH(CH 3)-CH 2 -O) o -(CH 2 -CH 2 -O) p -, - (CH 2 -CH 2 -O) n -(CH(CH 3)-CH 2 -O) o -, - (CH 2 -CH 2 -O) n -(CH 2 -CH(CH 3)-O) o -, - (CH 2 -CH(CH 3)-O) o -(CH 2 -CH 2 -O) n -, - (CH(CH 3)-CH 2 -O) o -(CH 2 -CH 2 -O) n -, - (CH 2 -CH(CH 3)-O) o -(CH 2 -CH 2 -O) n -(CH 2 -CH(CH 3)-O) q -, - (CH 2 -CH(CH 3)-O) o -(CH 2 -CH 2 -O) n -(CH(CH 3)-CH 2 -O) q -, - (CH(CH 3)-CH 2 O) o -(CH 2 -CH 2 -O) n -(CH 2 -CH(CH 3)-O) q - and - (CH(CH 3)-CH 2 O) o -(CH 2 -CH 2 -O) n -(CH(CH 3)-CH 2 -O) o -,
A toothbrush, comprising: a body with a speaker, wherein the speaker has an output opening, the output opening having a girth, wherein the bottom of the body is configured to rest against a surface when the toothbrush is oriented in a standing position; and wherein the speaker is configured to output an audio signal through the body of the toothbrush, characterized in that the girth of the output opening of the speaker is configured to be angled with respect to the surface to prevent water from contacting the speaker when the toothbrush is in the standing position. a body with a speaker, wherein the speaker has an output opening, the output opening having a girth, wherein the bottom of the body is configured to rest against a surface when the toothbrush is oriented in a standing position; and wherein the speaker is configured to output an audio signal through the body of the toothbrush, characterized in that the girth of the output opening of the speaker is configured to be angled with respect to the surface to prevent water from contacting the speaker when the toothbrush is in the standing position.
Computer-implemented method for providing output data, which is used for training and/or validating an algorithm, the processing result of which relates to an anatomical region of an examination subject that is mapped by the output data, comprising the steps: - receiving input data, which is raw data of a medical imaging method, wherein the anatomical region (52, 57, 81) and at least one further anatomical region (53, 58, 59, 82, 89) of the examination subject are at least partially mapped by the raw data, - generating output data by the raw data being modified in such a manner that the mapping of the further anatomical region (52, 57, 81) by the raw data is altered, in particular distorted, and - providing the output data, characterised in that the raw data is altered by at least one image data set (65, 66) being generated from the raw data by a reconstruction algorithm, wherein the further anatomical region (53, 58, 59, 82, 89) in the image data set (65, 66) is segmented and for each image data set (65, 66) a synthetic image data set, which exclusively maps the at least one further anatomical region (53, 58, 59, 82, 89), is generated, wherein the at least one synthetic image data set is processed by a mapping algorithm in order to generate synthetic raw data, wherein the output data is generated by the synthetic raw data being subtracted from the raw data. - receiving input data, which is raw data of a medical imaging method, wherein the anatomical region (52, 57, 81) and at least one further anatomical region (53, 58, 59, 82, 89) of the examination subject are at least partially mapped by the raw data, - generating output data by the raw data being modified in such a manner that the mapping of the further anatomical region (52, 57, 81) by the raw data is altered, in particular distorted, and - providing the output data, characterised in that the raw data is altered by at least one image data set (65, 66) being generated from the raw data by a reconstruction algorithm, wherein the further anatomical region (53, 58, 59, 82, 89) in the image data set (65, 66) is segmented and for each image data set (65, 66) a synthetic image data set, which exclusively maps the at least one further anatomical region (53, 58, 59, 82, 89), is generated, wherein the at least one synthetic image data set is processed by a mapping algorithm in order to generate synthetic raw data, wherein the output data is generated by the synthetic raw data being subtracted from the raw data.
An extract of Aloe vera comprising (i) 60 to 95% by weight of hydrolysed polysaccharides having a molecular weight in the range of 2 to 3 kDa; and (ii) less than 5% by weight polyphenols; wherein the polysaccharides are hydrolysed by trifluoroacetic acid. (i) 60 to 95% by weight of hydrolysed polysaccharides having a molecular weight in the range of 2 to 3 kDa; and (ii) less than 5% by weight polyphenols; wherein the polysaccharides are hydrolysed by trifluoroacetic acid.